On June 7, the FDA announced the historic fast-tracked approval of Biogen’s Aduhelm (aducanumab) for the treatment of Alzheimer’s disease. This is the first drug to target the pathophysiology of Alzheimer’s and significantly reduce amyloid beta plaque in patients.
There has not been an FDA-approved treatment for the disease since 2003, and we are tremendously delighted by this news.
MoCA Research & Innovation has been working with Biogen, and other major pharma, to not only test and validate treatment options –such as Aducanumab—but to also facilitate rapid comprehensive screening of MCI and early-stage Alzheimer’s among large populations.
Early detection of MCI/Alzheimer’s is imperative to ensure optimal management and outcome. And now, with novel treatments, progression of symptoms and disease conditions can be reduced or halted.
MoCA’s mission has always been to provide the most efficient assessment solutions for earliest diagnosis of MCI, and we are excited to share with you soon the most advanced versions we are working on.
Cheers to you, the medical community.
The MoCA Team